Holen Sie sich die Stockscreener-App
8.11
3.44%
0.27
Handel nachbörslich:
8.10
-0.010
-0.12%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.84
Offen:
$7.85
24-Stunden-Volumen:
1.25M
Relative Volume:
0.62
Marktkapitalisierung:
$1.04B
Einnahmen:
$628.25M
Nettoeinkommen (Verlust:
$-78.55M
KGV:
-13.08
EPS:
-0.62
Netto-Cashflow:
$-29.73M
1W Leistung:
+0.75%
1M Leistung:
-15.17%
6M Leistung:
-46.08%
1J Leistung:
-45.90%
1-Tages-Spanne:
$7.73
$8.145
1-Wochen-Bereich:
$7.4409
$8.69
52-Wochen-Spanne:
$6.08
$19.11
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Vergleichen Sie NEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
8.11 | 1.05B | 628.25M | -78.55M | -29.73M | -0.62 |
|
TMO
Thermo Fisher Scientific Inc
|
412.06 | 155.07B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.11 | 139.43B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
518.10 | 39.41B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
113.77 | 30.99B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
142.82 | 26.52B | 15.50B | 1.33B | 2.16B | 7.34 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
NeoGenomics opposes US PTAB discretionary denial, citing public health concerns - MLex
Guggenheim Begins Coverage of NeoGenomics (NEO) with Neutral Stance | NEO Stock News - GuruFocus
Guggenheim Initiates Coverage on NeoGenomics With Neutral Rating - marketscreener.com
NeoGenomics (NEO) Initiated with Neutral Rating by Guggenheim Analyst | NEO Stock News - GuruFocus
NEO Q1 Earnings Call: Sales Growth, Pharma Headwinds, and Pathline Integration Shape Outlook - Yahoo Finance
Insider Buying: Stephen Kanovsky Acquires Shares of NeoGenomics Inc (NEO) - GuruFocus
Chief Financial Officer of NeoGenomics Jeffrey Sherman Buys 14% More Shares - Yahoo Finance
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in oncology using the UG 100 sequencing platform - SelectScience
Insider Buying: Neil Gunn Acquires Shares of NeoGenomics Inc (NE - GuruFocus
Assessing NeoGenomics: Insights From 9 Financial Analysts - Benzinga
Piper Sandler Lowers Price Target on NeoGenomics (NEO) to $12.00 - GuruFocus
Piper Sandler Lowers Price Target on NeoGenomics (NEO) to $12.00 | NEO Stock News - GuruFocus
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays - Investing.com
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays - MarketBeat
NeoGenomics (NEO) Receives Adjusted Price Target from Piper Sand - GuruFocus
NeoGenomics (NEO) Receives Adjusted Price Target from Piper Sandler | NEO Stock News - GuruFocus
NeoGenomics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo
How to Take Advantage of moves in (NEO) - news.stocktradersdaily.com
NeoGenomics, Inc. to Host Earnings Call - ACCESS Newswire
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2025 Earnings Call Transcript - MSN
NeoGenomics (NEO) Price Target Lowered by Morgan Stanley | NEO S - GuruFocus
NeoGenomics (NEO) Price Target Lowered by Morgan Stanley | NEO Stock News - GuruFocus
NeoGenomics Repays $201.3 Million Convertible Senior Notes - marketscreener.com
NeoGenomics price target lowered to $10 from $17 at Morgan Stanley - Yahoo Finance
NeoGenomics clears $201.25M convertible debt ahead of maturity By Investing.com - Investing.com India
NeoGenomics clears $201.25M convertible debt ahead of maturity - Investing.com
NeoGenomics Pays Off 1.25% Convertible Senior Notes - Yahoo Finance
NeoGenomics (NEO) Shares Drop After Disappointing Q1 Revenue Rep - GuruFocus
NeoGenomics targets 25% annual NGS growth with new product launches in 2025 - MSN
NeoGenomics (NEO) Stock Target Reduced by Morgan Stanley Amid Q1 - GuruFocus
Leerink Partners Downgrades NeoGenomics (BMV:NEO) - Nasdaq
Health Care Stocks Rise As Pfizer And AstraZeneca Lead Gains - Finimize
NeoGenomics (NEO) Faces Price Target Cut Amid Significant Selloff | NEO Stock News - GuruFocus
NeoGenomics (NEO) Faces Price Target Reduction Amid Sales Challe - GuruFocus
NeoGenomics (NEO) Price Target Cut by BTIG Amid Revenue Concerns - GuruFocus
NeoGenomics stock hits 52-week low at $6.25 amid market challenges - Investing.com India
NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade) (NEO) - Seeking Alpha
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform - BioSpace
Visa To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
NeoGenomics Reports Strong Q1 2025 Performance - TipRanks
NeoGenomics (NEO) Kicks Off 2025 with Strong Revenue Momentum | - GuruFocus
NeoGenomics: Q1 Earnings Snapshot - MySA
NeoGenomics Reports Strong Q1 2025 Earnings Growth - TipRanks
NeoGenomics Q1 2025 Earnings Call Transcript - MarketBeat
NeoGenomics (NEO) Downgraded Amid Growth Concerns | NEO Stock Ne - GuruFocus
Why NeoGenomics (NEO) Stock Is Nosediving - MSN
Fort Myers-based NeoGenomics posts $26M net loss in Q1 - Gulfshore Business
Earnings call transcript: NeoGenomics Q1 2025 revenue misses forecast, stock drops - Investing.com Nigeria
NeoGenomics drops as sequential revenue decline leads to Q1 miss - MSN
NeoGenomics stock drops on Q1 miss (NEO:NASDAQ) - Seeking Alpha
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):